Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be…
Live: Hantavirus-infected patient hospitalised in Zurich as three more ‘evacuated’ from cruise ship
06/05/2026 – 14:14Air ambulance for suspected hantavirus patients leaves Cape Verde An air ambulance sent to retrieve three…
Association of reduced DTI-ALPS index and increased free water with glymphatic system alterations in noise-induced hearing loss: a neuroimaging study
Subjects According to the national standard of the People’s Republic of China, GBZ 49-2014 “Diagnosis of Occupational Noise…
Diagnostic performance evaluation of Elecsys anti-SARS-CoV-2 assay against RT-PCR for SARS-CoV-2 detection and surveillance in Ethiopian referral hospitals: cross-sectional study
Study setting This study was conducted in the Oromia Regional State of Ethiopia. Oromia is the largest of…
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Age-related diseases, including neurodegenerative diseases and cardiovascular and metabolic diseases, account for a substantial and rising portion of…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136,…